| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $270,205,223 ) (Continued on the next page) |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 000 | 2 | NIH | 12/5/2025 | $455,052 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 4 | NIH | 2/24/2026 | $774,089 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA295090 | MAPK-driven kinetochore stress in cancer | 000 | 2 | NIH | 4/1/2026 | $646,440 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UH3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 001 | 4 | NIH | 2/24/2026 | $812,783 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179457 | Early intervention with anti-proliferative therapy close to ART initiation to limit long-term SIV persistence | 000 | 3 | NIH | 4/21/2026 | $828,228 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13AI189265 | Flow Cytometry Workshops in Africa | 000 | 2 | NIH | 1/14/2026 | $69,132 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA289978 | Improving immune modulation for smoldering myeloma | 001 | 3 | NIH | 7/23/2026 | $687,234 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 000 | 4 | NIH | 2/19/2026 | $1,583,952 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 003 | 6 | NIH | 3/17/2026 | $1,105,868 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19MD020533 | CANOE Partnership: Cancer Awareness, Navigation, Outreach, and Enhanced Indigenous Health Outcomes | 000 | 3 | NIH | 7/24/2026 | $2,519,876 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 001 | 2 | NIH | 4/16/2026 | $54,890 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287476 | Interrogating a novel axis of tumor suppression in small cell lung cancer | 000 | 2 | NIH | 12/5/2025 | $494,025 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM144128 | Data analysis tools for leveraging massive public data to improve hypothesis-driven research | 000 | 6 | NIH | 2/23/2026 | $431,963 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM148166 | Biophysical and structural studies of protein and enzyme mechanism, evolution, and engineering | 000 | 4 | NIH | 5/27/2026 | $616,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM149357 | Mechanisms underlying chromosome segregation | 000 | 4 | NIH | 7/8/2026 | $352,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AG088347 | Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia | 000 | 3 | NIH | 7/3/2026 | $832,535 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24CA288185 | Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit | 001 | 4 | NIH | 8/26/2026 | $792,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177095 | Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | 000 | 3 | NIH | 1/30/2026 | $876,168 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24CA086368 | The Early Detection Research Network: Data Management and Coordinating Center | 005 | 26 | NIH | 8/26/2026 | $7,972,514 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 003 | 21 | NIH | 7/15/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 002 | 21 | NIH | 6/9/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 001 | 21 | NIH | 3/31/2026 | $764,777 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 000 | 21 | NIH | 12/9/2025 | $833,373 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 004 | 21 | NIH | 8/8/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 002 | 4 | NIH | 9/2/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 001 | 4 | NIH | 8/28/2026 | $199,820 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $7,493,366 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $279,066 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $273,482 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $1,597,854 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $273,482 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U24HL169645 | MOSAAIC Electronic Health Records Administrative Supplement | 000 | 4 | NIH | 8/14/2026 | $279,063 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI186721 | Phylodynamic mechanisms of HIV reservoir seeding and maintenance | 000 | 3 | NIH | 7/14/2026 | $857,037 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AG088223 | Tissue Mechanisms of Aging in the Genetic Model C. elegans | 000 | 3 | NIH | 6/3/2026 | $506,014 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 003 | 21 | NIH | 7/3/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 002 | 21 | NIH | 5/18/2026 | $3,267,164 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 001 | 21 | NIH | 4/30/2026 | $5,399,174 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 21 | NIH | 1/10/2026 | $10,875,343 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA289886 | A compass for those with relapsed leukemia after transplant | 001 | 3 | NIH | 6/19/2026 | $2,061,389 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175949 | A new humanized mouse model to study HBV gene editing | 000 | 3 | NIH | 8/14/2026 | $843,440 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA285227 | Rational Vaccine Design to prevent HIV-Associated Lymphoma | 001 | 3 | NIH | 4/16/2026 | $62,246 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA285227 | Rational Vaccine Design to prevent HIV-Associated Lymphoma | 000 | 3 | NIH | 1/30/2026 | $560,212 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01HG013177 | Statistical Methods for Inferring Gene-Phenotype Associations Using Omic Data from Gene Knockout and Human Phenotype Studies | 000 | 4 | NIH | 8/6/2026 | $551,382 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35CA253119 | The role and mechanism of alternative RNA splice variants and gene fusions as drivers of cancer | 001 | 7 | NIH | 8/14/2026 | $1,055,493 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | P50CA228944 | Fred Hutchinson Cancer Center Lung SPORE | 000 | 8 | NIH | 8/11/2026 | $2,407,128 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI147846 | Vaccine design to augment protective efficacy of antibodies against the EBV gH/gL glycoprotein complex | 001 | 7 | NIH | 3/30/2026 | $857,804 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL136135 | In vivo gene therapy for hemoglobinopathies with multiplexed virus-like particles | 001 | 10 | NIH | 8/5/2026 | $905,029 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA152637 | Fred Hutchinson Breast Cancer Clinical Validation Center | 000 | 16 | NIH | 8/5/2026 | $1,101,225 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R50CA211499 | A proteomics research specialist in developing targeted mass spectrometry methods for quantifying proteins important in cancer | 000 | 10 | NIH | 8/18/2026 | $310,761 |
|
